Gilead Sciences Shares Sold by Blair William & Co. IL

Institutional investor reduces stake in biopharmaceutical company

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Blair William & Co. IL, an institutional investor, reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% in the 3rd quarter, according to a recent SEC filing. The firm now owns 377,364 shares of the biopharmaceutical company's stock, valued at $41,887,000.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership can signal shifts in investor sentiment and influence the stock's performance.

The details

According to the filing, Blair William & Co. IL sold 8,983 shares of Gilead Sciences during the 3rd quarter. The firm's total holdings in the company now stand at 377,364 shares. Gilead Sciences has a market capitalization of $178.86 billion and its stock is currently trading around $144 per share.

  • The filing covers the 3rd quarter of the year.

The players

Blair William & Co. IL

An institutional investor that has reduced its stake in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Blair William & Co. IL's position in Gilead Sciences is a relatively minor change in institutional ownership, but it could signal a shift in investor sentiment towards the biopharmaceutical company. Investors will likely continue to monitor Gilead's financial performance and pipeline developments as the company navigates the competitive pharmaceutical landscape.